MedTrace Logo

Palatability of a Novel Oral Formulation of Prednsione

NCT02233959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2016-02-18

No results posted yet for this study

Summary

Prednisone solution USP (5mg/5mL), is the most commonly prescribed formulation of prednisone to pediatric and adult patients. The rationale for this study is that palatability is the most important determinant of pediatric patient compliance, and therefore, it is critical that the Orbis formulation be perceived as significantly more palatable compared to today's commercially available products in order to warrant further development of the TP.

Conditions

  • Palatability

Sponsors & Collaborators

  • Orbis

    collaborator OTHER

  • Arkansas Children's Hospital Research Institute

    lead OTHER

Principal Investigators

  • Gregory L Kearns, Pharm D. PhD · Children's Mercy Hospital Kansas City

Eligibility

Min Age
18 Years
Max Age
32 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02233959 on ClinicalTrials.gov